	US 11,921,116 B2
	Enigma and CDH18 as companion diagnostics for CDK4 inhibitors
Mary Elizabeth Dooley, New York, NY (US); Marta Kovatcheva, New York, NY (US); Samuel Singer, New York, NY (US); William D. Tap, New York, NY (US); Aimee Crago, New York, NY (US); and Andrew Koff, New York, NY (US)
Assigned to Memorial Sloan Kettering Cancer Center, New York, NY (US)
Appl. No. 16/083,425
Filed by Memorial Sloan Kettering Cancer Center, New York, NY (US)
PCT Filed Mar. 9, 2017, PCT No. PCT/US2017/021560 § 371(c)(1), (2) Date Sep. 7, 2018, PCT Pub. No. WO2017/156263, PCT Pub. Date Sep. 14, 2017.
Claims priority of provisional application 62/306,000, filed on Mar. 9, 2016.
Prior Publication US 2019/0310259 A1, Oct. 10, 2019
Int. Cl. G01N 31/00 (2006.01); C12Q 1/6886 (2018.01); G01N 33/53 (2006.01); G01N 33/574 (2006.01)

CPC G01N 33/57488 (2013.01) [C12Q 1/6886 (2013.01); G01N 33/574 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/70503 (2013.01); G01N 2333/70596 (2013.01); G01N 2800/52 (2013.01)]

13 Claims

1. A method for selecting cancer patients for treatment with a CDK4 inhibitor, comprising

(a) detecting CDH18 protein expression pattern within one or more cancer cells present in samples obtained from cancer patients;

(b) selecting cancer patients in which CDH18 protein is localized to foci within the one or more cancer cells; and

(c) administering an effective amount of a CDK4 inhibitor to the cancer patients of step (b), wherein the cancer is selected from the group consisting of liposarcoma, glioma, non-small cell lung cancer, and breast cancer.